33 results
SC 14D9/A
PRDS
Pardes Biosciences Inc
17 Aug 23
Tender offer solicitation (amended)
5:09pm
Strategies LLC, a strategic health care consulting firm, and currently serves on the board of directors of Amneal Pharmaceuticals, Inc. (NYSE: AMRX
SC 14D9
PRDS
Pardes Biosciences Inc
28 Jul 23
Tender offer solicitation
5:04pm
of the Pardes Board since July 2021. Ms. Autor is Chief Executive Officer of Autor Strategies LLC, a strategic health care consulting firm, and currently
8-K
EX-2.1
PRDS
Pardes Biosciences Inc
17 Jul 23
Entry into a Material Definitive Agreement
7:06am
payments to any foreign or domestic Governmental Official, employee or health care professional or to any foreign or domestic political parties … ) and other information (collectively, the “Health Care Submissions”) and (y) all such Health Care Submissions were complete and accurate
8-K
EX-10.1
PRDS
Pardes Biosciences Inc
18 May 23
Departure of Directors or Certain Officers
4:10pm
will have the right to continue group health care coverage for such benefits after May 31, 2023 under the law known as “COBRA” which will be described
424B3
ihesv tqvp21fz
7 Nov 22
Prospectus supplement
4:14pm
424B3
tmwkntvv7y
15 Aug 22
Prospectus supplement
5:41pm
424B3
pp2h10 arw7
10 May 22
Prospectus supplement
4:35pm
424B3
4uq8vizsvmsxyf30
1 Apr 22
Prospectus supplement
4:01pm
POS AM
swvadly
30 Mar 22
Prospectus update (post-effective amendment)
7:32am
10-K
EX-10.21
3zusq
29 Mar 22
Annual report
5:29pm
10-K
rmdlx24e14cxbxq5zk93
29 Mar 22
Annual report
5:29pm
424B3
amfgu2j4xttec15dvxl
1 Feb 22
Prospectus supplement
5:03pm